Although radiotherapy following orchidectomy is the treatment of choice for Stage I (negative lymphogram) and Stage IL (positive lymphogiam) patients with testicular teratoma, chemotherapy, either alone or in conjunction with radiotherapy is indicated when the disease has extended to extralymphatic structures such as liver or lung. Chemotherapy is also likely to play a part in the future as an adjunct to radiotherapy in those Stage II patients where there is a high risk of occult metastatic disease. Similarly, irradiation may prove to be valuable in association with chemotherapy in the management of more advanced disease to treat either bulky or residual tumour.
Multiple-drug chemotherapy was first used to treat patients with advanced testicular tumours by Li et al. (1960) who used a combination of chlorambucil, actinomycin D and methotrexate. Twelve out of 23 patients responded to treatment and 3 of these remained well for nine to eighteen months. Two of the 3 had an embryonal carcinoma (anaplastic teratoma) and 1 had a choriocarcinoma (trophoblastic teratoma). Mackenzie (1966) reported the results of chemotherapy in 154 patients with metastatic testis cancer and concluded that actinomycin D was the most effective single agent for the treatment of teratomas and the alkylating agent chlorambucil was the best drug for metastatic seminoma. The sensitivity of seminoma to alkylating agents had also been demonstrated by Blokhin et al. (1958) who had produced good regressions with sarcolysin, although there is no doubt that many of his patients would have been better treated by surgery and radiotherapy. In general, seminomas are very sensitive to alkylating agents, but treatment with chemotherapy should seldom be necessary in patients who have been properly managed with surgery and radiotherapy where the cure rate in all stages is 94% (Smithers 1972b).
In teratomas chemotherapy is often needed since these tumours may be widely disseminated at presentation or become so later. The rest of this paper will therefore be concerned only with chemotherapy for teratomas.
As newer drugs have become available their effect on testicular tumours has been tested.
Those which show the greatest promise have been vinblastine sulphate in high dosage (Samuels & Howe 1970) and mithramycin (Kennedy 1970 Remission lasted Total 31 more than two years in 9 patients one of these drugs. Thirty-one complete remissions have occurred with single agent treatment and 34 with combination treatment. Using this background information we have developed a combination of three of these first line drugs, vinblastine, actinomycin D and methotrexate (VAM), and used it to treat 20 patients with disseminated testicular teratoma. A report by Samuels (1971) that bleomycin was also effective in the management of these tumours stimulated us to try the effect of adding this drug to the combination when the tumour was nonresponsive or had become resistant to the combination. Twenty men with widespread testicular teratomas were treated. All had lung metastases at the time treatment was started and most of them also had lymph node metastases; 1 presented with brain metastases, and 8 had liver metastases; 1 patient had bone metastases. Details of the histology (Professor N F C Gowing) are as follows: 12 patients had anaplastic tumours, 3 had intermediate tumours, 2 had trophoblastic tumours and 3 had combined tumours. Chemotherapy: At first patients were given the VAM triple therapy over eight days as follows: vinblastine 10 mg i.v. on Days 1 and 8, actinomycin D 500 ,ug i.v. on Days 1-5 inclusive, methotrexate 100 mg i.v. on Days 1 and 8; folinic acid 21 mg i.m. six-hourly for six doses on Days 3, 4, 10 and 11. Folinic acid was given to reverse the side effects of the methotrexate.
Bleomycin 30 mg i.v. on Days 1-5 inclusive was added to the combination if the tumour did not respond to this treatment or became resistant after an initial response.
Later the scheduling of the drugs was modified in an attempt to reduce toxicity and to reduce the time spent by the patient in having treatment. The work of Price & Goldie (1971) had shown that very large doses of cytotoxic drugs could be given over short periods without producing unacceptable toxicity and therefore the combination was modified so that the total dose of all the drugs except bleomycin was given over twentyfour hours. The combination 'short VAM' is as follows: vinblastine 10 mg i.v., actinomycin D 2.0 mg i.v., methotrexate 200 mg in 1 litre of 50% dextrose i.v. over twenty-four hours immediately followed by folinic acid 21 mg i.m. six hourly for six doses. Courses of treatment were given as often as toxicity would allow. In practice this meant every month for VAM and every two to three weeks for 'short VAM'. Tamour response: A tumour was said to respond to treatment if its volume was reduced by 50 % or more by treatment. A less than 500% response in tumour volume was regarded as a failure. A complete remission was said to have occurred if there was no clinical or radiological evidence of tumour following treatment in a patient who was restored to normal health.
The majority of anaplastic tumours (11/12) responded to chemotherapy and 2 patients achieved complete remission. The response of the other types of tumours (2/8) was very much worse. An example of a response is shown in Fig  I A, B . This illustrates the complete disappearance of lung metastases in a 30-year-old man with an anaplastic teratoma following 1 course of short VAM. He remains apparently disease-free nine months from the start of chemotherapy. The addition of bleomycin to VAM produced little benefit. Only 1 patient out of 11 showed a significant response to bleomycin, which only lasted six weeks and for this reason bleomycin is no longer included in the combination. Toxicity: Nausea and vomiting were common side effects which could be controlled with chlorpromazine (200-300 mg daily). 'Short VAM' produced considerably less nausea than the eightday regime and was far better tolerated by the patients. Partial or complete epilation occurred in all our patients whatever drug regime was used. Skin rashes occurred in half the patients.
These were acneiform, often pustular and healed when treatment was discontinued, and are a side effect of actinomycin D.
Skin pigmentation, particularly in previously irradiated areas, and in areas involved by actinomycin-induced acne occurred in 4 out of the 11 patients who received bleomycin. Toxicity to the buccal mucous membrane and bone marrow was less common with the short VAM regime than with the eight-day treatments. Survival: Maximum follow-up time is fourteen months. Eight patients remain alive, 1 with no evidence of disease. He is a man of 30 with an anaplastic teratoma with lung metastases. It is too early to know what proportion, if any, of the patients will be long-term survivors, but 7 of the survivors to date have had anaplastic tumours and it seems probable that this group will live Causes of death: Twelve patients have died: 6 died with liver metastases, and it has been our experience that chemotherapy has been ineffective in controlling these when they were present before treatment was started, and has failed to prevent their appearance during treatment. Brain metastases have also been a problem in 3 patients and a cause of death in 1. This patient presented with brain metastases which were resistant to chemotherapy and only responded transiently to radiotherapy to the whole cranium. The other 2 patients developed brain metastases while their tumour was regressing in the lung. It is difficult not to conclude that the brain metastases grew while the lung metastases were regressing, due to failure of the drugs to cross the blood-brain barrier.
Human chorionic gonadotrophin (HCG): Urinary HCG levels have kindly been measured for us in the Edgar laboratory at Charing Cross Hospital (Dr K D Bagshawe) in all patients before chemotherapy was started and then immediately before each course of chemotherapy. Preliminary survival data would suggest that there may be a correlation between the level of urinary HCG at presentation and the survival of patients receiving chemotherapy. Ten patients had urinary HCG levels below 1000 units at presentation and 6 remain alive. Five of the 10 patients had urinary HCG levels of less than 100 units and 4 of these remain alive. Of the 10 patients whose urinary HCG levels were greater than 1000 units at presentation, only 2 remain alive. Clearly the number of patients is too small and the follow-up times are too short to draw any definite conclusions, but it seems that the urinary HCG titre at presentation may be a useful prognostic indicator.
Discussion
Combination chemotherapy can be effective in the management of widely disseminated testicular teratoma. Since we adopted the 'short VAM' regime toxicity has been acceptable and courses of treatment can be given at two to three week intervals at weekends, with only slight disruption of the patient's activities. Chemotherapy appears to be most effective at controlling lung metastases and least effective in controlling liver and brain metastases. In the case of the brain this is probably due to an inability of the drugs to cross the blood-brain barrier but with the liver the explanation is far from clear. Certainly the liver is a 'privileged site' as far as this group of tumours is concerned. If chemotherapy can be made more effective in controlling lung metastases in advanced cases it seems probable that a different approach, possibly brain and liver irradiation, is needed to eradicate metastases in these sites. At the present time we are exploring the feasibility of lymphatic and pulmonary irradiation following chemotherapy in those patients with Stage IV disease where there is no evidence of liver metastases and where extralymphatic spread is apparently confined to the lungs. The rationale of this approach is based upon the fact that although bulky disease responds dramatically to chemotherapy and tumour regression often occurs, large masses of teratoma are difficult to eradicate with radiotherapy but small volume residual disease may be more readily controlled. The influence of histology on response to chemotherapy which has been noted in all previous reports has been seen again in this series. It is really only the anaplastic teratomas which are consistently chemosensitive.
Since it is possible to eradicate large volumes of anaplastic tumours with chemotherapy, albeit transiently in most cases, this raises the possibility of using chemotherapy prophylactically following surgery and radiotherapy to increase the cure rate in patients whose disease is localized at the time of presentation. This approach has already been effective in cancers such as Wilms' tumour (D'Angio & Evans 1971), Ewing's tumour (Johnson & Pomeroy 1972) , and rhabdomyosarcoma (Pratt et al. 1972 ), in which the major cause of treatment failure in patients with apparently localized tumours has been failure to control the growth of microscopical metastases which are already established at the time of presentation. At The Royal Marsden Hospital 50% of men with Stage IL (testis and para-aortic nodes only involved) anaplastic teratomas treated with surgery and radiotherapy have failed to survive three years (Smithers 1972b) despite their being apparently disease free after treatment is completed. It is in a group such as this that the addition of prophylactic chemotherapy may help to prolong survival by the eradication of undetected small metastases. Patients with more advanced disease will remain the proving ground for the testing of new primary drug treatments. Smithers 
Radiotherapy of Testicular Tumours
Previous publications from the Testicular Tumour Unit of the Royal Marsden Hospital have reported the improvements which have occurred in the results of the radiotherapy of testicular tumours resulting from more precise clinical staging, the development of accurate radiation planning techniques and the introduction of super-voltage radiation equipment (Smithers 1972 , Smithers et al. 1971 . This report summarizes the results of treatment of patients with Stages 1, If and III seminoma and teratoma of the testis treated with radiotherapy between 1963 and 1971 and considers means whereby the prospects of patients with a high risk of disease relapse might be improved.
The clinical lymphographic staging is as follows: Stage I: tumour confined to testis (lymphogram negative). Stage HI: positive lymphogram (no supradiaphragmatic nodal disease). Stage III: supradiaphragmatic nodal disease (mediastinal and/or supraclavicular). Stage IV: extralymphatic spread (lungs, liver, brain &c.).
Histology
Histological material from patients in this series has been classified according to the histological classification adopted by the Testicular Tumour Panel of Great Britain (Collins & Pugh 1964 Staging All patients in this series had bilateral lower limb lymphograms. The lymphographic findings have recently been analysed (D W Wilkinson & J S Macdonald, in preparation) and a detailed study of the radiation response in relation to retroperitoneal tumour mass is in progress. The lymphogram was positive in 26 % of seminoma patients. In teratoma patients with no other evidence of extralymphatic spread the positive lymphogram rate was as follows: MTA 12/35 (34%), MTI 9/34 (27%), MT trophoblastic 2/4 patients, combined tumours (teratoma and seminoma co-existing in the same testis) 13/29 (43 %).
